empty cart | close cart

Your cart

Your cart is empty.

Get a quote close form

Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.

Tecan Journal dot

Selected category: Oncology

Back to overview

A very short history of cancer research funding

In his book The Emperor of All Maladies, Siddhartha Mukherjee tells the story of one of the turning points in the history of cancer medicine. A turning point that he dates to May 1947.

Read more

Ramping up NGS in oncology: is sequencing tumor DNA enough?

Massively parallel sequencing has rapidly become a must-have tool of the trade in molecular biology and drug discovery research. In recent years, the cost of next generation sequencing (NGS) has declined exponentially, while throughput, accuracy and read lengths have soared, and multiple regulatory-compliant sequencing technologies have now achieved commercial success. Advances in NGS – combined with global efforts to identify and catalog genetic mutations in a range of cancer types and tumors, as well as to implement these discoveries in diagnostic, therapeutic and prognostic applications – are driving the adoption and, in the not-too-distant future, even routine use of sequencing and related techniques in clinical laboratories.

Read more